Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...

Of 94 patients with locally advanced or metastatic NSCLC who received trastuzumab rezetecan as second- or later-line ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).